Jorge Eduardo Cortés
Has participated in:
-
Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios
-
Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML
-
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial
-
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review